首页/数据集/Dataset from Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder

Dataset from Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder

NIAID Data Ecosystem2026-05-10 收录

膀胱过度活动症临床试验

药物疗效安全性

数据链接：

https://doi.org/10.25934/PR00010613 数据链接链接失效反馈

官方服务：

资源简介：

This study is to assess the efficacy and safety of YM178 in patients with symptoms of overactive bladder.

应用场景：

创建时间：

2025-12-23

晚期肝癌治疗优化

药物疗效安全性

Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-che

Mendeley Data2024-06-25 更新60

Supplementary Material for: Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies

肾性贫血治疗

药物疗效安全性

Background: Molidustat, a novel hypoxia-inducible factor-prolyl hydroxylase inhibitor, is being investigated for the treatment of anemia associated with chronic kidney disease (CKD). The efficacy and

Figshare2019-03-08 更新40

MOESM2 of Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases

罕见病系统评价

药物疗效安全性

Additional file 2. This file includes all the references screened in the systematic review and the reason for exclusion.

Figshare2019-10-22 更新10

RE covery and SUR vival of patients with moderate to severe acute RE spiratory distress syndrome (ARDS) due to C OVID-19: a multicenter, single-arm, Phase IV itolizumab T rial: RESURRECT

COVID-19治疗

药物疗效安全性

Itolizumab, an anti-CD6 monoclonal antibody, down-regulates COVID-19-mediated inflammation and the acute effects of cytokine release syndrome. This study aimed to evaluate the safety and efficacy of i

DataCite Commons2024-08-09 更新50

Data_Sheet_1_Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.ZIP

射血分数保留心力衰竭治疗

药物疗效安全性

AimsThe efficacy and safety of sacubitril/valsartan for patients with heart failure with preserved ejection fraction (HFpEF) are controversial. Hence, the primary objective of the study was to evaluat

NIAID Data Ecosystem40

Dataset from Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder

资源简介：

相关数据集